Back to Browse Journals » Biologics: Targets and Therapy » Volume 2 » Issue 2

Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications

Authors Paul N Knoebl

Published 6 June 2008 Volume 2008:2(2) Pages 285—296


Paul N Knoebl

Department of Medicine 1, Division Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria

Abstract: The protein C pathway has an important function in regulating and modulating blood coagulation and ensuring patency of the microcirculation. Protein C deficiency leads to macro- and microvascular thrombosis. Congenital severe protein C deficiency is a life-threatening state with neonatal purpura fulminans and pronounced coagulopathy. Patients with heterozygous protein C deficiency have an increased risk for thromboembolic events or experience coumarin-induced skin necrosis during initiation of coumarin therapy. Replacement with protein C concentrates is an established therapy of congenital protein C deficiency, resulting in rapid resolving of coagulopathy and thrombosis without reasonable side effects. This article summarizes the current knowledge on protein C replacement therapy in congenital protein C deficiency.

Keywords: protein C, deficiency, replacement therapy, purpura fulminans, coagulopathy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Hepatocellular carcinoma: natural history, current management, and emerging tools

Tinkle CL, Haas-Kogan D

Biologics: Targets and Therapy 2012, 6:207-219

Published Date: 17 July 2012

Integrins and extracellular matrix in mechanotransduction

Ramage L

Cell Health and Cytoskeleton 2012, 4:1-9

Published Date: 28 December 2011

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

Tariq I Mughal, Andrew Schrieber

Biologics: Targets and Therapy 2010, 4:315-323

Published Date: 2 December 2010

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)

Leigh D Church, Sinisa Savic, Michael F McDermott

Biologics: Targets and Therapy 2008, 2:733-742

Published Date: 5 December 2008

Bevacizumab in the treatment of HER2-negative breast cancer

Vito Lorusso

Biologics: Targets and Therapy 2008, 2:813-821

Published Date: 5 December 2008

Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside

Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago Redondo

Biologics: Targets and Therapy 2008, 2:397-407

Published Date: 12 September 2008

Novel targets for immunotherapy in glomerulonephritis

Mary H Foster

Biologics: Targets and Therapy 2008, 2:531-545

Published Date: 12 September 2008

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias

Aldo M Roccaro, Irene M Ghobrial, Simona Blotta, Steven P Treon, Michele Malagola, et al

Biologics: Targets and Therapy 2008, 2:419-431

Published Date: 12 September 2008

Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures

Neil Ghodadra, Kern Singh

Biologics: Targets and Therapy 2008, 2:345-354

Published Date: 12 September 2008

Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)

Andrea Pession, Fraia Melchionda, Claudia Castellini

Biologics: Targets and Therapy 2008, 2:129-141

Published Date: 7 March 2008